Glancy Prongay & Murray LLP Commences Investigation on Behalf of Fresenius Medical Care AG & Co. KGAA Investors
January 09 2017 - 4:50PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of Fresenius Medical Care AG & Co. KGAA
(“Fresenius” or the “Company”) (NYSE: FMS) investors concerning the
Company and its officers’ possible violations of federal securities
laws. GPM is preparing a lawsuit on behalf of Fresenius
investors.
Fresenius is a kidney dialysis company that provides dialysis
treatment and related dialysis care services, and other health care
services.
On January 7, 2017, Fresenius disclosed that it was in receipt
of subpoenas from federal prosecutors in connection with the
Company’s relationship with the American Kidney Fund, a charity
that provides financial aid to patients for kidney dialysis.
On this news, Fresenius stock has fallen as much as 6.70%, to
$39.70 during intra-day trading on January 9, 2017.
If you purchased Fresenius securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109006418/en/
Glancy Prongay & Murray LLP, Los Angeles/New YorkLesley
Portnoy, 310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2024 to May 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From May 2023 to May 2024